[1] Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013[J]. Lancet, 2015,385(9963):117-171.
[2] 《中国心血管健康与疾病报告》编写组.《中国心血管健康与疾病报告2020》概述[J].中国心血管病研究, 2021.19(7): 582-590.
[3] Malakar A K, Choudhury D, Halder B, et al.A review on coronary artery disease, its risk factors, and therapeutics[J]. J Cell Physiol, 2019,234(10):16812-16823.
[4] 心血管植入物血管内器械第2部分:血管支架[S]. 中华人民共和国医药行业标准,YY/T 0663,2-2016.
[5] Song J, Kouidri S, Bakir F.Review on the numerical investigations of mass transfer from drug eluting stent[J]. Biocybern Biomed Eng, 2021,41(3):1057-1070.
[6] Sotomi Y, Onuma Y, Collet C, et al.Bioresorbable scaffold the emerging reality and future directions[J]. Circ Res, 2017,120(8):1341-1352.
[7] Buccheri D, Piraino D, Andolina G,et al.Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment[J]. J Thorac Dis, 2016,8(10):1150-1152.
[8] Tanaka A, Jabbour R J, Mitomo S, et al.Hybrid percutaneous coronary intervention with bioresorbable vascular scaffolds in combination with drug-eluting stents or drug-coated balloons for complex coronary lesions[J]. JACC Cardiovasc Interv, 2017,10(6):539-547.
[9] Sousa J E, Costa M A, Abizaid A, et al.Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study[J]. Circulation, 2001,103(2):192-195.
[10] 国家食品药品监督管理总局医疗器械技术审评中心.冠状动脉药物洗脱支架临床试验指导原则[EB](2018年第21号).
[11] Kirtane AJ, Gupta A, Iyengar S, et al.Safety and efficacy of drug-eluting and bare metal stents comprehensive meta-analysis of randomized trials and observational studies[J]. Circulation, 2009,119(25),3198-3206.
[12] Raber L, Magro M, Stefanini GG, et al.Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study[J]. Circulation, 2012,125(9):1110-1121.
[13] Tada T, Byrne RA, Simunovic I, et al.Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents results from a registry of 18,334 patients[J]. JACC Cardiovasc Interv, 2013,6(12):1267-1274.
[14] Moreno R, Fernández C, Hernández R, et al.Drug-eluting stent thrombosis results from a pooled analysis including 10 randomized studies[J].J Am Coll Cardiol,2005,45(6): 954-959.
[15] Joner M, Finn AV, Farb A, et al.Pathology of drug-eluting stents in humans delayed healing and late thrombotic risk[J]. J Am Coll Cardiol, 2006,48(1): 193-202.
[16] Virmani R, Giulio G, Farb A, et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious?[J].Circulation 2004,109(6):701-705.
[17] Levine GN, Bates ER, Bittl JA, et al.ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelies[J]. Circulation, 2016,134(10):123-155.
[18] McQueen A, Escuer J, Aggarwal A, et al. Do we really understand how drug eluted from stents modulates arterial healing?[J]. Int J Pharm, 2021,601(2):120575-120575.
[19] Nogic J, McCormick LM, Francis R, et al. Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents[J]. J Cardiol, 2018,71(5): 435-443.
[20] Serruys PW, Farooq V, Kalesan B, et al.Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomized, Noninferiority Trial[J]. JACC: Cardiovasc Interv, 2013,6(8):777-789.
[21] Chen W, Habraken TCJ, Hennink WE, et al.Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents[J]. Bioconjug Chem,2015,26(7):1277-1288.
[22] Urban P, Meredith IT, Abizaid A, et al.Polymer-free drug-coated coronary stents in patients at high bleeding risk[J]. New Eng J med, 2015,373(21):2038-2047.
[23] Maes F, Costerousse O, Cieza T, et al.Transradial experience with bioresorbable vascular scaffolds: a case-matched study with metallic drug-eluting stents[J].Cardiovasc Revasc Med, 2018,19(6):700-704.
[24] 周生刚,游远琪,徐阳,等.生物可降解金属基支架的应用进展[J]. 昆明理工大学学报(自然科学版),2021,3(46):18-26.
[25] 王洋洋,吴红枚,甄文强,等.生物可降解血管支架研究进展[J].中国医疗器械杂志,2021,45(4):410-415.
[26] Serruys PW, Garcia-Garcia HM, Onuma Y.From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?[J]. Eur Heart J,2012,33(1):16-25.
[27] Karanasiou GS, Papafaklis MI, Conway C, et al.Stents: biomechanics, biomaterials, and insights from computational modeling[J]. Ann Biomed Eng, 2017,45(4):853-872.
[28] Cassese S, Byrne RA, Ndrepepa G, et al.Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials[J]. Lancet,2016,387(10018):537-544.
